TY - JOUR
T1 - The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia
T2 - Findings from a longitudinal observational cohort
AU - Takahashi, Tatsuichiro
AU - Uchida, Hiroyuki
AU - John, Majnu
AU - Hirano, Jinichi
AU - Watanabe, Koichiro
AU - Mimura, Masaru
AU - Correll, Christoph U.
AU - Kishimoto, Taishiro
N1 - Funding Information:
Funding for this study was supported in part by Astellas Foundation of Research on Metabolic Disorders, the Japanese Society of Neuropsychopharmacology, The Zucker Hillside Hospital Mental Advanced Center for Intervention and Services Research for the Study of Schizophrenia (MH090590) from the National Institute of Mental Health, Bethesda, Md.
Funding Information:
Dr. Uchida has received grants from Pfizer, Astellas Pharmaceutical, Eisai, Otsuka Pharmaceutical, Pharmaceutical, GlaxoSmithKline, Shiohogi, and Dainippon-Sumitomo Pharma, Eli Lilly, Mochida Pharmaceutical, Meiji-Seika Pharma, Janssen Pharmaceutical, and Yoshitomi Yakuhin and speaker's honoraria from Otsuka Pharmaceutical, Janssen Pharmaceutical, Novartis Pharma, Eli Lilly, Shionogi, GlaxoSmithKline, Yoshitomi Yakuhin, Dainippon-Sumitomo Pharma, and Janssen Pharmaceutical.
Funding Information:
Dr. Correll has been a consultant and/or advisor to or has received honoraria from: Actelion, Alexza; American Academy of Child and Adolescent Psychiatry, AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Gerson Lehrman Group, GSK, IntraCellular Therapies, Lundbeck, Medavante, Medscape, Merck, National Institute of Mental Health, Novartis, Ortho-McNeill/Janssen/J&J, Otsuka, Pfizer, ProPhase, Sunovion, Takeda, Teva, and Vanda. He has received grant support from BMS, Feinstein Institute for Medical Research, Janssen/J&J, National Institute of Mental Health (NIMH), National Alliance for Research in Schizophrenia and Depression (NARSAD), and Otsuka. He is also a shareholder of Alexza stock options.
PY - 2013/7
Y1 - 2013/7
N2 - To examine the effect of prolactin-raising antipsychotics on bone mineral density (BMD), data of 164 schizophrenia patients who received ?. 2 dual-energy x-ray absorptiometry scans were analyzed (49.3% men; mean. ±. SD age: 58.5. ±. 11.0. years; duration of treatment: 26.7. ± 13.8. years). Patients were divided into a prolactin-raising antipsychotic (n = 141) or prolactin-sparing (n = 23) group, and time x group interaction was examined using mixed effect model. Although the BMD difference did not reach significance over 3.4. ± 1.6. years, a significant antipsychotic-class vs. time interaction was found (p = 0.011), indicating a negative impact of prolactin-raising antipsychotics on BMD. Large-scale, randomized-controlled data are required to replicate and extend these findings.
AB - To examine the effect of prolactin-raising antipsychotics on bone mineral density (BMD), data of 164 schizophrenia patients who received ?. 2 dual-energy x-ray absorptiometry scans were analyzed (49.3% men; mean. ±. SD age: 58.5. ±. 11.0. years; duration of treatment: 26.7. ± 13.8. years). Patients were divided into a prolactin-raising antipsychotic (n = 141) or prolactin-sparing (n = 23) group, and time x group interaction was examined using mixed effect model. Although the BMD difference did not reach significance over 3.4. ± 1.6. years, a significant antipsychotic-class vs. time interaction was found (p = 0.011), indicating a negative impact of prolactin-raising antipsychotics on BMD. Large-scale, randomized-controlled data are required to replicate and extend these findings.
KW - Antipsychotics
KW - Bone mineral density
KW - Dual-energy x-ray absorptiometry
KW - Prolactin
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=84879004266&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879004266&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2013.04.015
DO - 10.1016/j.schres.2013.04.015
M3 - Article
C2 - 23668975
AN - SCOPUS:84879004266
VL - 147
SP - 383
EP - 386
JO - Schizophrenia Research
JF - Schizophrenia Research
SN - 0920-9964
IS - 2-3
ER -
